APIs

Dabigatran Etexilate Mesylate * Anticoagulant
Product USDMF CEP EDMF China DMF CADIFA Brazil KDMF Russia ANVISA BRAZIL Therapeutic Use
Aripiprazole Antipsychotic/Antidepressant
Articaine HCl Anesthetic
Atomoxetine HCl ** Attention Deficit Hyperactivity Disorder (ADHD)
Baclofen * * Skeletal Muscle Relaxant
Benserazide Anti-Parkinson
Betahistine DiHCl * * Anti-Vertigo
Buspirone Anti-anxiety
Calcium Acetate Phosphate-removing Agent
Cilostazol * Antiplatelet
Dabigatran Etexilate Mesylate * Anticoagulant
Dapagliflozin propanediol monohydrate * * * * Antidiabetic
Desvenlafaxine * Antidepressant
Dexmethylphenidate HCl Attention Deficit Hyperactivity Disorder (ADHD)

Show More

Product Therapeutic Use Status
Apixaban Anticoagulant Under Validation
Acotiamide Anti-Dyspepsia Under Validation
Dexlansoprazole Proto Pump Inhibitors Lab Validation
Edoxaban Anticogulant Under Validation
Erdosteine Mucolytic Agent Under Validation
Hydroxyzine Pamoate Antihistamine Validation Completed
Indapamide Antihypertensive Under Validation
Lercanidipine Antidepressant, Anxiolytic Validation Completed
Loxoprofen Non-Steroidal Anti-Inflammatory Validation Completed

Show More

Pellets

Product Name DMF/Tech Pack Bio equivalence established (Y/N) Type of BE study Fast/Fed RLD/Mkt Stability Brazil Turkey Mexico MENA APAC
Duloxetine HCl Delayed Release Pellets 20% (HPMC Acetyl Succinate) DMF Yes Fast & Fed CYMBALTA / EU Available 36 M Yes Yes Yes Yes Yes
Duloxetine HCl Delayed Release Pellets 20% (HPMC Phthalate) DMF/Tech Park Yes Fasting & Fed CYMBALTA / Turkey/ EU Available 36 M No No No No Yes
Duloxetine Delayed Release Pellets 17% (HPMC Phthalate) DMF/Tech Park No No Available 12 M Yes No No Yes Yes
Itraconazole Immediate Release Pellets 21.74% DMF Yes Fasting & Fed SPORANOX / US Available 36 M No No Yes No Yes
Itraconazole Immediate Release Pellets
22%
DMF No No Available 36 M Yes No Yes Yes Yes
Venlafaxine HCl Extended Release Pellets 33% Dossier/DMF Yes Fasting & Fed EFFEXOR / EU Available 36 M Yes Yes Yes Yes Yes
Omeprazole Delayed Release Pellets 8.5% (LD-30) Dossier/DMF No No Available 36 M No No Yes Yes Yes
Omeprazole Delayed Release Pellets 8.5% (Phthalate) Dossier/DMF Yes Fast & Fed Customer Established BE in Indonesia Available 36 M No No Yes Yes Yes

Show More

Product   Name DMF/ Tech Pack Bioequivalence Established Type of BE Study RLD/Mkt Stability Brazil Turkey Mexico MENA APAC
Duloxetine Hydrochloride Delayed Release Pellets
17%
Tech Pack No No No 6M data available
Trimetazidine Extended Release Pellets 55% Tech Pack No No VASTAREL MR/ Brazil 6M data available Yes
Dabigatran Etexilate Pellets 35% Tech Pack No Fast Single Dose Study PRADAXA/ US 3M data available Yes

Show More

Finished Dosage Forms

Product Strength ANDA (Approved/Filed) EU Dossier (Approved/Filed) ANDS (Approved/Filed) Countries for which Dossier are available
Baclofen Tablets 5mg Approved Not Filed Except USA
Baclofen Tablets 10mg Approved Not Filed Except USA
Baclofen Tablets 20mg Approved Not Filed Except USA
Cinacalcet tablets 30 mg Approved Approved Can be offered globally
Cinacalcet tablets 60 mg Approved Approved Can be offered globally
Cinacalcet tablets 90 mg Approved Approved Can be offered globally
Doxazosin tablets 1 mg Filed Not filed Approved in CA Except USA, Canada
Doxazosin tablets 2 mg Filed Not filed Approved in CA Except USA, Canada

Show More

Product Strength Status
FERRIC CITRATE Tablets EQ210 IRON Proof of concept established
Aspirin+Dipyridamole ER Capsules 25/200mg Proof of concept established
Mexiletine Capsules 150mg/200mg/250mg Proof of concept established
Diflunisal tablets 500 mg Proof of concept established
Dipyridamole ER capsules 200 mg Proof of concept established
Solifenacin & Tamsulosin PR tablets 6 mg/0.4 mg Proof of concept established
Hydralazine HCl tablets 10 mg, 25 mg, 50 mg   and 100 mg Proof of concept established
Tamsulosin MR tablets 0.4mg Under development

Show More

Your API deserves more than a manufacturer. It deserves a partner.